Joseph P. Fuhr, Jr, PhD, professor emeritus, Widener University, discusses interchangability in biosimilars.
Transcript (slightly modified)
How important is interchangeability for biosimilars?
Interchangeability is not important. There are 2 type of biologics: pharmacy, and physician-administered. In physician-administered, interchangeability will not matter, since the physician is picking the drug directly, so (there is) no need to substitute. In a pharmacy scenario, automatic substitution will occur, but are payers willing to pay a price premium for an interchangeable biologic?
Biosimilars are highly similar, so how much better is an interchangeable biologic? It is highly, highly similar, so if (the) copay is greater for (an) interchangeable, then will patients pay more for it?
Also, it costs more for an interchangeable study, since you need to do switching studies, which add to cost. So are firms willing to take on this investment with very little gain? There is 1-year exclusivity for interchangeables for each reference product, but other biosimilars will probably be in the market before this occurs.
Also, some believe they may not be able to apply without some post-market data—which will delay entry—and not be allowed to apply initially for interchangeability. Also, if they don’t get approved for interchangeability, will this hurt the image of (the) product and (its) market share? There’s too much risk for too little reward to go for interchangeability.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.